* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's PEG Ratio or its related term are showing as below:
FRA:B6E'
s PEG Ratio Range Over the Past 10 Years
Min: 0.18 Med: 0.64 Max: 7.84
Current: 4.89
During the past 13 years, Swedish Orphan Biovitrum AB's highest PEG Ratio was 7.84. The lowest was 0.18. And the median was 0.64.
FRA:B6E's PEG Ratio is ranked worse than 80.22% of 369
companies
in the Drug Manufacturers industry
Industry Median: 1.76
vs FRA:B6E: 4.89
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Swedish Orphan Biovitrum AB PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Swedish Orphan Biovitrum AB's PEG Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's PEG Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's PEG Ratio falls into.
Swedish Orphan Biovitrum AB PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Swedish Orphan Biovitrum AB (FRA:B6E) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Swedish Orphan Biovitrum AB PEG Ratio Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (FRA:B6E) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:B6E has been successfully added to your 